Fam-Trastuzumab Deruxtecan-Nxki

Introduction Overview

Generic Name

fam-trastuzumab deruxtecan-nxki

Brand Name

Enhertu

Dosage Form

intravenous powder for injection

Drug Class

HER2 inhibitors

Pharmacokinetics

Absorption:
Trastuzumab deruxtecan is administered intravenously, thereby bypassing gastrointestinal absorption barriers associated with oral drugs. After reconstitution, the drug is delivered directly into systemic circulation, allowing immediate and complete bioavailability of the antibody-drug conjugate (ADC). IV administration also provides precise control over dosing and pharmacokinetic profiles, important for optimizing therapeutic effects.

Distribution:
Once in systemic circulation, trastuzumab deruxtecan demonstrates targeted distribution primarily to tissues expressing the HER2 receptor due to its antibody component, trastuzumab. The ADC binds selectively to HER2-overexpressing cancer cells, facilitating cellular uptake via receptor-mediated endocytosis. This targeted mechanism reduces systemic exposure of the cytotoxic payload. The conjugated deruxtecan has a moderate molecular weight, limiting extensive tissue distribution, but allows penetration into tumor tissues. The volume of distribution is relatively low, consistent with large molecule therapeutics.

Metabolism:
Trastuzumab deruxtecan undergoes intracellular processing primarily through lysosomal degradation following receptor-mediated endocytosis into HER2-positive cancer cells. The antibody component is catabolized by proteolytic enzymes into amino acids and small peptides, which are recycled or eliminated. The deruxtecan moiety, a topoisomerase I inhibitor, is released intracellularly as an active metabolite to exert cytotoxic effects by inducing DNA breaks. Systemic metabolism of the released deruxtecan occurs extensively in the liver via cytochrome P450 enzymes, predominantly CYP3A4, generating inactive metabolites.

Elimination:
Clearance of trastuzumab deruxtecan is mediated through both proteolytic degradation and normal reticuloendothelial system processes handling monoclonal antibodies. The elimination half-life of the ADC ranges approximately 5 to 6 days, enabling dosing every three weeks. The released deruxtecan is eliminated primarily via hepatic metabolism with subsequent renal excretion of metabolites. Minor elimination occurs through biliary excretion. Renal clearance of the intact ADC is negligible due to its large molecular size. Dose adjustments may be required in patients with hepatic or renal impairment to prevent accumulation and toxicity.

Dosage Forms

Available Dosage Forms:
Trastuzumab deruxtecan is provided as a single-dose vial containing 100 mg of fam-trastuzumab deruxtecan-nxki in a powder form intended for intravenous infusion after reconstitution and dilution. This vial formulation allows precise dosing based on patient weight.

Dosages for Adults and Adolescents:
- Unresectable or Metastatic HER2-Positive Breast Cancer and HER2-Positive Solid Tumors: 5.4 mg/kg administered intravenously every three weeks (21-day cycle) until disease progression or unacceptable toxicity.
- Unresectable or Metastatic HER2-Mutant Non-Small Cell Lung Cancer (NSCLC): 5.4 mg/kg IV every three weeks.
- Locally Advanced or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma: Higher dosing of 6.4 mg/kg IV every three weeks, reflecting different pharmacodynamic requirements in this patient population.

Specific Patient Populations:
- Infusion Rate and Duration: Initial infusion lasts over 90 minutes; subsequent infusions may be administered over approximately 30 minutes if prior doses were well tolerated.
- Dose adjustments or interruptions are recommended in patients who develop severe adverse reactions or in the presence of renal or hepatic impairment to mitigate toxicity.
- Patients with lung or cardiac comorbidities require careful monitoring due to risk of serious adverse events.
- Pregnancy and breastfeeding are contraindicated due to teratogenicity and unknown milk excretion.
- Due to immunosuppressive effects, prophylactic anti-nausea and supportive care regimens are advised to manage adverse events.
Comprehensive clinical guidelines recommend administration under supervision in oncology infusion centers with availability of management protocols for infusion-related reactions.

Mechanism Of Action

Trastuzumab deruxtecan is an antibody-drug conjugate (ADC) that harnesses the specificity of targeted monoclonal antibody therapy combined with a potent chemotherapeutic agent. The antibody component, trastuzumab, selectively binds to the human epidermal growth factor receptor 2 (HER2), a transmembrane tyrosine kinase receptor overexpressed in certain cancers. By binding HER2, trastuzumab deruxtecan blocks proliferative signaling pathways that drive tumor growth and survival. This targeted binding ensures preferential delivery of the cytotoxic payload to HER2-expressing cancer cells.

Upon binding to HER2, the ADC-receptor complex undergoes internalization through receptor-mediated endocytosis into the cancer cell. This intracellular trafficking directs the conjugate to lysosomes where proteolytic enzymes cleave the linker connecting the antibody to the cytotoxic payload, deruxtecan. Deruxtecan is a derivative of exatecan and functions as a topoisomerase I inhibitor, interfering with DNA replication by inducing single-strand DNA breaks. The accumulation of DNA damage leads to apoptosis of tumor cells.

Importantly, trastuzumab deruxtecan features a cleavable tetrapeptide-based linker that is stable in circulation but selectively cleaved by tumor-associated lysosomal proteases. This design minimizes systemic release and off-target toxicity while maximizing tumor-specific cytotoxicity. Additionally, the membrane-permeable properties of deruxtecan allow a bystander effect, inducing death in adjacent HER2-low or negative tumor cells within the tumor microenvironment, potentially enhancing the therapeutic response.

Comparatively, trastuzumab deruxtecan differs from other HER2-targeted therapies such as trastuzumab (Herceptin) which lack the cytotoxic conjugate, and ado-trastuzumab emtansine (Kadcyla), another ADC but with a different linker and payload. Clinical trials demonstrate that trastuzumab deruxtecan's enhanced delivery and potent payload result in superior efficacy in metastatic HER2-positive and HER2-low cancers, expanding its therapeutic utility. Ongoing research continues to evaluate the molecular mechanisms contributing to resistance and optimize dosing strategies.

Pharmacological Actions

Selective HER2 receptor binding and blockade of HER2-mediated signaling pathways.
Targeted intracellular delivery of a potent topoisomerase I inhibitor (deruxtecan) to HER2-positive tumor cells.
Induction of DNA damage resulting in apoptosis of malignant cells.
Bystander cytotoxic effect on neighboring HER2-low or negative cells due to membrane-permeable payload.
Antibody-dependent cellular cytotoxicity (ADCC) via immune effector mechanisms.
Prolonged plasma half-life characteristic of monoclonal antibody-based therapeutics.
Synergistic combination of targeted therapy and chemotherapy within one molecular construct.
Reduced systemic toxicity compared to conventional chemotherapeutics owing to tumor-targeted delivery.
Activation of lysosomal degradation pathways following receptor-mediated endocytosis.
Inhibitory effect on heterogeneous HER2-expressing tumor cell populations.
Overcomes some resistance mechanisms encountered in prior HER2-targeted therapies.
Demonstrated clinical efficacy in metastatic HER2-positive and HER2-low breast cancer, gastric cancer, and NSCLC.

Therapeutic Or Clinical Uses

Treatment of unresectable or metastatic HER2-positive breast cancer in adults with prior anti-HER2 therapy.
Management of unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer following chemotherapy.
Treatment of HER2-ultralow and hormone receptor-positive breast cancer progressing after endocrine therapy.
Therapy for unresectable or metastatic HER2-mutant non-small cell lung cancer (NSCLC).
Management of locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma after trastuzumab-based regimen.
Treatment of unresectable or metastatic HER2-positive solid tumors with prior chemotherapy and no satisfactory alternatives.
Used in adult patients requiring precision oncology interventions targeting HER2 abnormalities.
Indicated for patients with disease progression despite prior standard treatments.
Option for patients with aggressive and advanced-stage HER2-overexpressing malignancies.
Provides a novel mechanism of action combining targeted therapy with cytotoxic chemotherapy.
Utilized under oncology specialist supervision with regular monitoring for toxicity.
Part of multidisciplinary regimens in metastatic cancer care protocols.
Included in treatment algorithms based on FDA approvals and clinical guideline endorsements.
Shown to improve progression-free survival and overall response rates in pivotal clinical trials.

Side Or Adverse Effects

Hair loss (alopecia) commonly observed during treatment.
Nausea and vomiting, often requiring prophylactic antiemetics.
Loss of appetite leading to weight loss and nutritional challenges.
Gastrointestinal disturbances including diarrhea and constipation.
Respiratory symptoms such as cough and potential interstitial lung disease (ILD).
Fever and fatigue contributing to general malaise during therapy.
Muscle and joint pain impacting quality of life.
Hematological toxicities including low blood cell counts (neutropenia, anemia, thrombocytopenia).
Electrolyte imbalances such as hypokalemia.
Abnormal liver function tests indicative of hepatic stress or damage.
Infusion-related reactions ranging from mild to severe, including chest tightness and wheezing.
Serious pulmonary toxicity manifested as pneumonitis requiring immediate medical attention.
Immune suppression leading to increased risk of infections and bleeding tendencies.
Potential cardiotoxicity, including arrhythmias and heart failure symptoms.
Rare but severe allergic reactions necessitating emergent care.

Precautions

Monitor for lung or breathing issues before and during treatment to detect interstitial lung disease early.
Assess for signs and symptoms of infection given immunosuppressive potential.
Baseline and periodic cardiac evaluation recommended due to risk of cardiotoxicity.
Pregnancy testing required prior to initiation; effective contraception mandatory during and post-therapy.
Avoid breastfeeding during treatment and for at least seven months after the last dose.
Dose adjustments necessary in patients with renal or hepatic impairment.
Frequent monitoring of complete blood counts to detect and manage cytopenias promptly.
Management of infusion-related reactions with readiness to slow or stop infusion as needed.
Counsel patients on possible fertility effects and discuss fertility preservation if indicated.
Educate patients on recognizing serious adverse effects such as dyspnea, chest pain, or unusual bruising.
Avoid co-administration with medications that may exacerbate QT prolongation or increase toxicity.
Use caution with concomitant therapies that suppress immune function.
Regular liver function testing to identify hepatotoxicity early.
Adherence to scheduling of infusions is important; do not delay doses without medical advice.
Promptly report any new or worsening symptoms to healthcare providers.

Warnings

Risk of serious or life-threatening interstitial lung disease and pneumonitis; immediate evaluation required if respiratory symptoms arise.
Potential for cardiotoxicity including arrhythmias and heart failure; monitor cardiac function vigilantly.
Immunosuppression may increase susceptibility to infections and bleeding complications; monitor closely.
Severe infusion-related reactions may occur; infusion should be slowed or discontinued based on severity.
Not safe for use during pregnancy; causes fetal harm evidenced by animal studies and clinical data.
Potential impairment of fertility in male patients; discuss reproductive risks prior to therapy.
Avoid breastfeeding during treatment and for a prolonged period following last dose due to unknown excretion in milk.
Concomitant use with other topoisomerase I inhibitors or chemotherapeutic agents may increase toxicity.
Dose interruptions or discontinuation recommended with severe adverse events or organ dysfunction.
Use with caution in patients with preexisting lung or heart conditions due to increased risk of complications.
Monitoring for laboratory abnormalities such as cytopenias and elevated liver enzymes is critical.
Careful patient selection and risk-benefit assessment essential before initiating therapy.
Ensure availability of emergency resources during infusions for rapid management of hypersensitivity.
Treatment discontinuation should be considered if unbearable toxicity or progressive organ damage occurs.
Patient counseling to recognize and promptly report warning signs enhances safety.

Contraindication

Known hypersensitivity to fam-trastuzumab deruxtecan or any component of the formulation.
Pregnancy due to teratogenic and embryotoxic potential.
Breastfeeding women to prevent potential drug exposure to infants.
Patients with prior severe infusion reactions to trastuzumab deruxtecan or related compounds.
Concomitant use with other agents contraindicated due to overlapping toxicity.
Preexisting severe interstitial lung disease or pneumonitis not manageable with treatment.
Uncontrolled cardiac disease that contraindicates further cardiotoxic therapies.
Patients unable to comply with monitoring requirements for toxicity.
Known active infections or conditions that significantly increase risk of treatment complications.
Severe hepatic or renal impairment when dose adjustment is not feasible or safe.
Patients with bleeding diatheses exacerbated by potential thrombocytopenia.
Use not recommended in pediatric populations due to lack of established safety.
Unstable or rapidly progressing disease where benefit-risk ratio is unfavorable.
Allergy to excipients such as polysorbate 80 present in the formulation.
Inability to receive intravenous infusions safely.

Drug Interactions

Concurrent administration with strong CYP3A4 inhibitors may increase deruxtecan exposure and toxicity.
Use with other chemotherapeutic agents targeting topoisomerase I requires caution due to additive toxicities.
Co-administration of immunosuppressants may potentiate immunosuppression and risk of infections.
Potential interaction with anticoagulants may increase bleeding risks amid thrombocytopenia.
Medications that prolong QT interval should be used cautiously to avoid cardiac arrhythmias.
Live vaccines should be avoided during treatment due to immunosuppressive effects.
Nonsteroidal anti-inflammatory drugs or corticosteroids may affect bleeding risk.
Agents causing hepatotoxicity may exacerbate liver enzyme abnormalities associated with trastuzumab deruxtecan.
Drugs metabolized by CYP3A4 may compete with deruxtecan metabolism affecting drug levels.
Herbal supplements with CYP3A4 induction or inhibition properties could alter efficacy or toxicity.
Concomitant use of nephrotoxic drugs requires vigilance due to possible renal impairment.
Drug interactions that impair bone marrow function may worsen cytopenias.
Modifications in therapy may be needed when combining with agents affecting electrolyte balance.
Monitor closely for signs of additive infusion reactions with other monoclonal antibodies.
Patients should inform healthcare providers of all medications to avoid unknown interactions.

Preparations Of The Drug

Enhertu is supplied as a single-dose vial containing 100 mg of fam-trastuzumab deruxtecan-nxki powder for intravenous injection.
The powder must be reconstituted and diluted according to manufacturer guidelines prior to administration.
Inactive ingredients include L-histidine, L-histidine hydrochloride monohydrate, polysorbate 80, and sucrose to stabilize the formulation.
Stored refrigerated between 2°C and 8°C (36°F to 46°F), with protection from light until use.
Do not freeze the vials or shake reconstituted/diluted solutions to maintain stability and efficacy.
Packaging provides dosage precision for weight-based dosing regimens common in oncology treatments.
Prepared infusion solutions must be handled in controlled settings maintaining aseptic technique.
Pharmaceutical preparation requires use by trained healthcare professionals in authorized facilities.
Detailed prescribing information (package insert) available to guide safe preparation and administration.
The product carries the J-code J9358 for billing and reimbursement purposes in intravenous chemotherapy.
Distributor and manufacturer information: Daiichi Sankyo, Inc., and AstraZeneca Pharmaceuticals LP.
Preparation protocols include guidelines for infusion duration and management of infusion-related reactions.
Disposal of unused or expired product must follow biohazard and chemotherapy waste regulations.
No biosimilar products currently marketed; Enhertu is the reference biological product.
Patient education materials and healthcare provider resources are available to support optimal use.